Development of antibody drugs targeting against HER2 for cancer therapy / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1297-1305, 2012.
Article
in Chinese
| WPRIM
| ID: wpr-274662
ABSTRACT
Human epidermal growth factor receptor 2 (HER2) belongs to the transmembrane glycoprotein receptor family. Overexpression of HER2 could directly lead to tumorigenesis and metastasis. This phenomenon could be observed in the breast cancer, ovarian cancer, gastric cancer, lung cancer and prostate cancer. Compared with the conventional chemotherapy, the targeted treatment of antibody is more specific and has lower side effects. This review describes the current status of monotherapy and combination therapies of anti-HER2 antibodies, trastuzumab and pertuzumab, with chemotherapeutic drugs. The development trends of new formats of anti-HER2 antibody drugs such as bispecific antibody, immunotoxin are also discussed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Therapeutics
/
Immunotoxins
/
Drug Delivery Systems
/
Receptor, ErbB-2
/
Immunoconjugates
/
Therapeutic Uses
/
Antibodies, Monoclonal, Humanized
/
Trastuzumab
/
Metabolism
/
Neoplasms
Limits:
Humans
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS